Eli Lilly and Company (NYSE:LLY) FY Conference March 02, 2026 03:10 PM ET Company ParticipantsLucas Montarce - EVP and CFOMichael Czapar - SVP of Investor RelationsConference Call ParticipantsSteve Scala - Pharmaceutical AnalystNone - AnalystNone - AnalystSteve ScalaOne's 46th Annual Healthcare Conference. We are absolutely delighted to have Eli Lilly back at the conference again this year. Representing the company is Lucas Montarce, who is the CFO, as well as Mike Czapar, who is the Head of Investor Relati ...

Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake [Purchase Licensing Rights, opens new tab]- Companies[Eli Lilly and Co]FollowMarch 2 (Reuters) - Eli Lilly [(LLY.N), opens new tab] CFO Lucas Montarce said on Monday it is pr ...

Key Takeaways Eli Lilly received a positive CHMP opinion to expand Olumiant use in adolescents with severe AA.Phase III data showed 42% patients with severe AA achieved at least 80% scalp hair coverage at 36 weeks.Olumiant recorded sales worth $1.01B in 2025; U.S. adolescent decision expected in H2 2026.Eli Lilly (LLY) and Incyte (INCY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending the approval of the e ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, as its valuation hovers around $1 trillion. It has generated fantastic gains for investors, rising by more than 400% in just the past five years. Those are terrific returns for a stock that's a fairly safe blue chip investment. But with such impressive gains, you may be wondering whether it's too late to invest in the stock, whether there's still room for it to rise, or if it's due for a correction. Below, I'll look to answer thos ...

In this articleNVOLLYNVONovo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capacities to make the newly launched Wegovy pill, the Danish drugmaker said Monday. The news comes about two months after Novo launched its blockbuster weight loss drug Wegovy in pill form in the U.S. market, in what has been described as one of the strongest launches ever. "With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities f ...

Key Takeaways Novo Nordisk stock fell 21% after CagriSema lost to Zepbound in the phase III REDEFINE 4 obesity study.Lilly's orforglipron beat Rybelsus in ACHIEVE-3, cutting A1C by 2.2% and weight by 9.2% at 52 weeks.Novo Nordisk plans to cut U.S. list prices of Wegovy, Ozempic and Rybelsus to $675 monthly by 2027.Novo Nordisk (NVO) has endured a brutal week, with its shares plunging 21% after a series of disappointing clinical results and mounting pricing pressures erased virtually all the gains accumulate ...

The drug and biotech sector has recovered somewhat in 2026 after remaining muted for most of 2025. Drug pricing agreements of Big Pharma with the Trump administration, strong quarterly results, bullish outlook for 2026, robust pipeline activity and a flurry of M&A deals have led to the industry’s recovery. However, it faces its share of headwinds like regular pipeline setbacks, slow ramp-up of newer drugs, patent cliffs, regulatory risks and policy and pricing uncertainty. Despite the headwinds, the industr ...

Core Insights - Lehigh Valley is experiencing a manufacturing renaissance, particularly in the life sciences sector, highlighted by Eli Lilly's $3.5 billion investment for a new facility focused on weight loss therapies [1][2] Investment Highlights - Eli Lilly's investment is the largest from the life sciences sector in Pennsylvania's history, with the US weight loss market projected to reach $148.7 billion by 2031 [2] - The facility is expected to be operational by 2031, positioning Lehigh Valley as a key player in meeting the demand for weight loss medications [2] Strategic Development - The initiative for Eli Lilly's investment began in the summer of 2024, with the Lehigh Valley Economic Development Corporation actively courting the company for a different pharmaceutical facility [3] - The region's workforce development efforts included collaboration with community colleges to align technical training with Eli Lilly's needs, emphasizing the availability of skilled pharmaceutical talent [4] Competitive Landscape - Lehigh Valley initially lost the bid for an earlier facility to Virginia but was later successful in securing the new site, outperforming over 300 other applicants [4][6] - Eli Lilly cited the region's proximity to STEM universities, strong technical manufacturing economy, and established infrastructure as key factors in their site selection [6]

证券研究报告 医药生物 行业定期报告 hyzqdatemark 2026 年 03 月 02 日 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 孙洁玲 SAC：S1350524120004 sunjieling@huayuanstock.com 联系人 板块表现： 礼来口服减肥药上市在即，建议关注相关机会 投资评级： 看好（维持） ——医药行业周报（26/2/24-26/2/27） 投资要点： 请务必仔细阅读正文之后的评级说明和重要声明 证券分析师 本周医药市场表现分析：2 月 24 日至 2 月 27 日，医药指数上涨 0.50%，相对沪深 300 指数 超额收益为-0.58%。上周全市场主要集中在周期板块，化工、有色等涨价主题板块表现较好， 医药整体表现一般，创新药持续调整。进入三月份，我们建议关注 Q1 业绩较好的个股，同时 布局基本面优质、超跌的创新药个股，当前阶段可侧重关注涨价预期的方向。1）创新药建议 关注，A 股）恒瑞医药、信立泰、泽璟制药、热景生物、科伦药业、上海谊众、福元医药、苑 东生物；港股）中国生物制药、三生制药、信达生物、康方生物、科 ...

The maker of the high-selling tirzepatide injectable medication sold under the "We are an innovative company with an innovative product, and we price based on the value delivered to patients, physicians, and the healthcare system," Tucker said in an interview. "Tirzepatide is priced for the value it provides. Generic markets are separate...There is room for both segments.""Also, we offer both prefilled monthly pen and vial options, which gives patients some flexibility," said Tucker.His comments come ahead ...